<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 Sec File Number
0-27642
FORM 12b-25
CUSIP Number
NOTIFICATION OF LATE FILING 893636 10 0
(Check One): [x] Form 10-K [ ] Form 20-F [ ] Form 11-K
[ ] Form 10-Q [ ] Form N-SAR
For Period Ended: December 31, 1998
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ______________
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
________________________________________________________________
PART I - REGISTRANT INFORMATION
Transderm Laboratories Corporation
Full Name of Registrant
Former Name if Applicable
460 Park Avenue, Suite 1300
Address of Principal Executive Office (Street and Number)
New York, NY 10022
City, State and Zip Code
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed. (Check box if
appropriate)
(a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without
unreasonable effort or expense;
<PAGE>
[xx] (b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form 20-F, 11-K, Form
N-SAR, or portion thereof, will be filed on or before
the fifteenth calendar day following the prescribed due
date; or the subject quarterly report of transition
report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the
prescribed due date; and
(c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K,
11-K, 10-Q, N-SAR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
SEE ATTACHED
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in
regard to this notification
Ronald J. Burghauser 717 764-1191
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section
13 or 15(d) of the Securities Exchange Act of 1934 or
Section 30 of the Investment Company Act of 1940 during
the preceding 12 months (or for such shorter) period
that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
[ x ] Yes [ ] No
(3) Is it anticipated that any significant change in
results of operations from the corresponding period for
the last fiscal year will be reflected by the earnings
statement to be included in the subject report or
portion thereof?
[ x ] Yes [ ] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state
the reasons why a reasonable estimate of the results cannot
be made.
SEE ATTACHED
<PAGE>
TRANSDERM LABORATORIES CORPORATION
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date March 31, 1999 By /s/ Ronald J. Burghauser
Ronald J. Burghauser
Vice President Finance
<PAGE>
<PAGE>
Addendum to Form 12b-25 dated March 31, 1999
for
Transderm Laboratories Corporation
Part III
Registrant is a 90%-owned subsidiary of Health-Chem Corporation
("Health-Chem"). Registrant's financial statements are included
in the consolidated financial statements of Health-Chem. Health-
Chem is concurrently filing a Form 12b-25 extending the time to
file its Annual Report on Form 10-K for the fiscal year ended
December 31, 1998 to April 15, 1999 because of an inability to
make reasonable estimates regarding net realizable values in
respect of Health-Chem's previously announced sale process
involving its Herculite Products, Inc. and Hercon Environmental
Corporation subsidiaries. Registrant requires such estimates to
enable it to prepare accurate financial statements. Although
there can be no assurance, Registrant has been advised that
Health-Chem expects to be in a position to provide such estimates
that would allow Registrant to file its Annual Report on Form 10-
K for the fiscal year ended December 31, 1998 on or before April
15, 1999.
